OncoDNA SA has become the first shareholder of IntegraGen SA (Paris: ALINT), holding 29.99% of the existing shares, as result of purchases of shares on the Euronext Growth market .
These acquisitions of shares of IntegraGen follow the filing of a draft friendly takeover bid on the shares of IntegraGen SA with the French Autorité des Marchés Financiers (AMF) on July 9th 2020.
At the date of filing of the draft offer, OncoDNA did not own any share of IntegraGen.
The acquisitions of shares representing 29.99% of the share capital of IntegraGen have been made on the market at the offer price of 2.20 EUR/share in accordance with applicable regulations.
The public offer remains subject to the approval of the AMF and clearance by the French Ministry of Economy under foreign investment control in France, and is expected to be opened at the end of the third quarter of 2020.
OncoDNA remains enthusiast about the transaction and waits for the next steps of the process. This transaction would bring together OncoDNA’s expertise in oncology precision medicine and IntegraGen’s know-how in DNA sequencing services and bioinformatics analyses. The combination of both companies would enable to offer a complete solution that combines most advanced oncology laboratory testing and software solutions which will benefit the treatment of patients with advanced cancer.
El gen AtCDF3 promueve una mayor producción de az...
Un estudio con datos de los últimos 35 años, ind...
Un equipo de investigadores de la Universidad Juli...
En nuestro post hablamos sobre este interesante tipo de célula del si...
Horizon ha puesto en funcionamiento una nueva planta dedicada íntegra...
Portal de biotecnología en España
¡Suscríbase a nuestro newsletter para estar al día con las últimas noticias y ofertas!
2013 © Biotech-Spain.com - Site Developments SL. Todos los derechos reservados. Terminos y Condiciones | Política de Privacidad
Articles
Directory